Research Database

To evaluate whether daraxonrasib improves survival compared to chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma...

To evaluate the safety, efficacy, and early ctDNA reduction of RMC-6236 in patients with previously treated RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Why oncogenic KRAS mutations alone are insufficient to cause full cancer transformation.

AFNT-111 is a TCR-engineered cellular therapy designed to target the KRASG12V mutation, a common driver in pancreatic, colorectal, and lung cancers, with the...

This study evaluates the safety and preliminary anti-tumor activity of FH-A11KRASG12V-TCR, an autologous T cell therapy targeting the KRAS G12V mutation in...

To develop and evaluate JAB-23425, a novel orally bioavailable inhibitor targeting multiple KRAS mutants (e.g., G12D, G12V, G13D) beyond the previously...

Discovery of HYP-2A, a second-generation KRASG12C inhibitor designed to overcome resistance to existing drugs like Sotorasib and Adagrasib in KRASG12C-mutant...

To develop a pan-KRAS inhibitor (JAB-23E73) that targets multiple KRAS mutations, including those resistant to existing therapies.

This narrative review examines the evolution of direct RAS inhibitors, focusing on how previously 'undruggable' RAS mutations—especially KRASG12C—are now being...